OrbiMed Israel BioFund GP Limited Partnership 13D and 13G filings for Chemomab Therapeutics Ltd.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-09-16 4:34 pm Sale | 2024-09-12 | 13D | Chemomab Therapeutics Ltd. CMMB | OrbiMed Israel BioFund GP Limited Partnership | 1,860,906 9.990% | -409,185 (-18.03%) | Filing |
| 2024-03-11 7:19 pm Unchanged | 2024-03-11 | 13D | Chemomab Therapeutics Ltd. CMMB | OrbiMed Israel BioFund GP Limited Partnership | 2,270,091 16.000% | 0 (Unchanged) | Filing |
| 2023-11-15 4:35 pm Unchanged | 2023-11-14 | 13D | Chemomab Therapeutics Ltd. CMMB | OrbiMed Israel BioFund GP Limited Partnership | 2,270,091 18.300% | 0 (Unchanged) | Filing |
| 2023-01-05 4:31 pm Sale | 2023-01-03 | 13D | Chemomab Therapeutics Ltd. CMMB | OrbiMed Israel BioFund GP Limited Partnership | 2,270,091 19.700% | -49,869,729 (-95.65%) | Filing |
| 2021-03-26 4:06 pm Purchase | 2021-03-16 | 13D | Chemomab Therapeutics Ltd. CMMB | OrbiMed Israel BioFund GP Limited Partnership | 52,139,820 24.300% | 52,139,820 (New Position) | Filing |